MINI FUTURE LONG - ELI LILLY & CO | Real-time Euronext Paris 10:53:37 2024-05-22 EDT | ||
| 20.52 EUR | -2.01% |
|
| Current month | +11.09% | ||
| 1 month | +43.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 20.52 | -2.01% |
| 24-05-21 | 20.94 | +11.86% |
| 24-05-20 | 18.72 | +5.47% |
| 24-05-17 | 17.74 | -3.53% |
| 24-05-16 | 18.4 | -0.65% |
Real-time Euronext Paris
Last update May 22, 2024 at 10:53 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| ZK8NB | |
| ISIN | FRBNPP06JOC6 |
| Date issued | 2024-03-04 |
| Strike | 577.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 18.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.92 € |
|---|---|
| Lowest since issue | 13.6 € |
| Spread | 0.05 € |
| Spread % | 0.24% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- ZK8NB Certificat